NCT00248313View on ClinicalTrials.gov

Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus

PHASE3CompletedINTERVENTIONAL
Enrollment

470

Participants

Timeline

Start Date

July 31, 2000

Study Completion Date

October 31, 2007

Conditions
Kidney Disease
Interventions
DRUG

Rapamune®

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00248313 - Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus | Biotech Hunter | Biotech Hunter